Upadacitinib Improves Giant Cell Arteritis in Phase 3 Trial

by Medscape • 2024/06/14 • 0 Comments

Results from the SELECT-GCA study showed upadacitinib (Rinvoq) induced significant and sustained remission in people with new-onset or relapsing giant cell arteritis.
Medscape Medical News

← Licaminlimab has positive effect on dry eye signs in phase 2b trial

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock →

Post navigation